Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rigontec brings in €9.45mm via Series A; adds €4.8mm via second tranche; gets another €15mm

Executive Summary

Rigontec GMBH (RNA-based immunotherapies for cancer and viral diseases) raised €9.45mm ($11.98mm) in its Series A financing co-led by Wellington Partners and Boehringer Ingelheim Venture Fund, which each add a board member, and were joined in the round by NRW.Bank and High-Tech Gründerfonds.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies